Last updated: June 3, 2021
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Overall Status: Active - Recruiting
Phase
N/A
Condition
Lymphoma
Lymphoma, B-cell
Hematologic Cancer
Treatment
N/AClinical Study ID
NCT04914143
2020-261
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Diffuse large B-cell lymphoma,NOS
- all patients were diagnosed for the first time
- between 18-75 years old, male and female
- ECoG 0-3 ,the expected survival was more than 6 months
- the pregnancy test of women of childbearing age was negative; Male and female patientsshould agree to take effective contraceptive measures during the treatment period andone year of follow-up;
- sign the informed consent before the test screening
Exclusion
Exclusion Criteria:
- those who are known to be allergic to the study drug or its related components; Orallergic patients
- uncontrolled psychosis
- participating in other trials at the same time, and using experimental drugs that mayaffect the efficacy and safety evaluation
- impairment of liver and kidney function
- HIV antibody positive;
- HBsAg positive hepatitis B carriers and confirmed hepatitis B and C patients;
- pregnant or lactating women and patients who do not agree to take effectivecontraceptive measures;
- the patient is unable to swallow the capsule or has a disease or condition thatseriously affects the gastrointestinal function;
Study Design
Total Participants: 120
Study Start date:
June 06, 2020
Estimated Completion Date:
December 30, 2023
Connect with a study center
2ndAffiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, Zhejiang 310000
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.